LEO Pharma Acquires Rare Disease Drug for $435M

LEO Pharma is significantly bolstering its rare dermatology portfolio with the acquisition of worldwide rights to the investigational oral therapy dersimelagon from Tanabe Pharma. The strategic move, valued at up to $435 million in upfront and near-term milestone payments, signals LEO Pharma's commitment to addressing severe unmet needs in genetic skin disorders.

Dersimelagon, a once-daily oral MC1R agonist, is being developed for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). These rare genetic conditions inflict debilitating sunlight-induced skin damage, severely restricting patients' quality of life and outdoor activities. The drug's mechanism aims to enhance skin melanin, thereby reducing light penetration and mitigating painful phototoxic reactions. The candidate has already garnered FDA Fast Track and Orphan Drug designations, underscoring its potential therapeutic significance.

The acquisition aligns with LEO Pharma's established strategy of expanding its rare disease footprint. This follows recent collaborations, including a 2025 partnership with Boehringer Ingelheim for Spevigo and the acquisition of Replay's gene therapy platform. The company anticipates increased investment in 2026 for pre-launch preparations and in 2027 for a potential market introduction, contingent on regulatory approvals.

Tanabe Pharma recently presented compelling Phase 3 INSPIRE study results, demonstrating statistically significant improvements in key endpoints. Notably, the study showed a marked increase in the average daily sunlight exposure patients could tolerate before experiencing symptoms. This data supports the potential for dersimelagon to become the first oral therapeutic option for EPP and XLP, a significant advancement given the current treatment landscape. The New Drug Application was submitted to the FDA in June 2026.

This transaction represents a substantial opportunity for LEO Pharma to leverage its global reach and deep expertise in medical dermatology. As stated by Christophe Bourdon, CEO of LEO Pharma, the company sees dersimelagon as a "compelling opportunity to expand our rare dermatology pipeline with a late-stage oral therapy candidate." Similarly, Akihisa Harada, CEO of Tanabe Pharma, highlighted LEO Pharma's suitability to "realize the full potential of dersimelagon and, if approved, bring this innovative treatment to patients."

The market for rare dermatological conditions, while niche, presents significant opportunities for specialized therapies. The potential approval of dersimelagon could establish a new standard of care, offering a much-needed oral alternative to existing management strategies. The deal, which is subject to customary closing conditions and regulatory review, saw J.P. Morgan Securities advise LEO Pharma as financial advisor, with Latham & Watkins providing legal counsel.